Treating stubborn melasma, particularly when exacerbated by the Australian summer heat, requires a multi-modal approach that addresses both ultraviolet (UV) radiation and infrared-induced heat stress. The primary strategy involves the 'triple therapy' approach or high-potency tyrosinase inhibitors such as hydroquinone, tranexamic acid, and cysteamine, which work by interrupting the melanogenesis pathway [1]. Because heat triggers vasodilation and melanocyte stimulation, topical cooling agents and systemic antioxidants like Polypodium leucotomos can provide an internal buffer against thermal-induced pigment synthesis [2].
To effectively clear persistent patches, you must transition from simple SPF to broad-spectrum physical blockers containing iron oxides. These provide a physical shield against visible light, which is now recognised as a major driver of melasma recurrence that standard chemical filters may not fully block [3]. Incorporating a topical retinoid at night helps accelerate cell turnover, shedding pigmented keratinocytes, while anti-inflammatory agents like niacinamide help to stabilise the skin barrier, reducing the micro-inflammation that heat often causes in sensitive Australian complexions [4].
Melasma is a complex chronic hypermelanosis characterised by symmetrical brown macules, primarily on face. Its pathogenesis involves not just melanocytes, but a dysfunctional dermal environment including increased vascularity, mast cell infiltration, and solar elastosis [1][5]. Unlike standard post-inflammatory hyperpigmentation, melasma is highly sensitive to hormonal fluctuations and thermal energy, making it particularly difficult to manage in climates with high UV indices and ambient temperatures.
Recent biomedical research highlights the role of the Transient Receptor Potential Vanilloid 1 (TRPV1) ion channel, which is activated by heat. When the skin temperature rises, TRPV1 triggers the release of pro-melanogenic cytokines, explaining why melasma often worsens even when one stays in the shade but remains in a hot environment [2]. Effective management therefore focuses on suppressing these biological pathways while physically cooling the skin and inhibiting the enzymatic conversion of tyrosine to melanin.
For those managing the appearance of heat-induced pigment, AUREME formulated the C-Veil Citrine Tonic with a blend of Vitamin C and Niacinamide to help brighten and support a more even skin tone. To further address the dullness often associated with stubborn discolouration, some of our customers incorporate Solenne Oil, which utilises Bakuchiol as a gentle, plant-based alternative to support overnight renewal without the irritation often linked to traditional retinoids.
FAQ
Why does heat make melasma worse even if I wear sunscreen?
Heat induces vasodilation and increases the expression of vascular endothelial growth factor (VEGF). This process promotes a pro-inflammatory environment that signals melanocytes to produce more pigment [2][5]. Furthermore, most standard sunscreens only protect against UV, failing to block the infrared radiation and visible light that contribute to thermal melanogenesis [3].
Is oral tranexamic acid safe for treating melasma?
Low-dose oral tranexamic acid (TXA) has emerged as a highly effective treatment for recalcitrant melasma. It works by inhibiting the plasminogen/plasmin pathway, which reduces the interaction between melanocytes and keratinocytes [6]. While generally safe, it requires a medical consultation to rule out contraindications like a history of thromboembolic disease [6].
What role do iron oxides play in melasma protection?
Iron oxides are essential for melasma patients because they provide protection against high-energy visible (HEV) light, also known as blue light. Research indicates that blue light induces more persistent pigmentation in darker skin phenotypes than UV radiation alone [3][7]. Finding a tinted moisturiser or sunscreen containing iron oxides is a critical step for summer stabilisation [7].
References:
[1] Handel AC, et al. Melasma: a clinical and epidemiological review. Anais Brasileiros de Dermatologia. 2014;89(5):771-782. doi:10.1590/abd1806-4841.20143063
[2] Lee AY. Recent progress in melasma pathogenesis. Pigment Cell & Melanoma Research. 2015;28(6):648-660. doi:10.1111/pcmr.12404
[3] Boukari F, et al. Prevention of melasma relapses with sunscreen providing protection against visual light and ultraviolet A. Journal of the American Academy of Dermatology. 2015;72(1):189-190. doi:10.1016/j.jaad.2014.08.023
[4] Navarrete-Solis J, et al. A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma. Dermatology Research and Practice. 2011;2011:379173. doi:10.1155/2011/379173
[5] Kim M, et al. The role of vascular endothelial growth factor in the hyperpigmentation of melasma. Journal of Dermatological Science. 2007;48(2):131-133. doi:10.1016/j.jdermsci.2007.06.007
[6] Bala HR, et al. Oral Tranexamic Acid for the Treatment of Melasma: A Review. Dermatologic Surgery. 2018;44(6):814-825. doi:10.1097/DSS.0000000000001518
[7] Dumas M, et al. The effect of visible light on skin hyperpigmentation. Journal of Investigative Dermatology. 2021;141(4):957-965. doi:10.1016/j.jid.2020.08.028
